ReviewHeart failure reviews2017
Angiogenic growth factors in myocardial infarction: a critical appraisal.
Review in Heart failure reviews, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 25 citations in OpenAlex.
- Finerenone attenuates myocardial injury and enhances vascular repair via regulation of autophagy, apoptosis, and angiogenesis.Scientific reports · 2026Article
- Cardiac mural cells are rate-limiting for coronary vascularization after heart injury.iScience · 2025Article
- AREGMolecular medicine (Cambridge, Mass.) · 2025Article
- Endothelial-to-mesenchymal transition enhances permissiveness to AAV vectors in cardiac endothelial cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Recombinant human placental growth factor-2 in post-infarction left ventricular dysfunction: a randomized, placebo-controlled, preclinical study.Basic research in cardiology · 2024Article
- GTF2H4 regulates partial EndMT via NF-κB activation through NCOA3 phosphorylation in ischemic diseases.Innovation (Cambridge (Mass.)) · 2024Article
- Myocardial angiogenesis induced by concurrent vitamin D supplementation and aerobic-resistance training is mediated by inhibiting miRNA-15a, and miRNA-146a and upregulating VEGF/PI3K/eNOS signaling pathway.Pflugers Archiv : European journal of physiology · 2023Article
- ERK/HIF-1α/VEGF pathway: a molecular target of ELABELA (ELA) peptide for attenuating cardiac ischemia-reperfusion injury in rats by promoting angiogenesis.Molecular biology reports · 2022Article
- Bone morphogenetic protein 1.3 inhibition decreases scar formation and supports cardiomyocyte survival after myocardial infarction.Nature communications · 2022Article
- Transthoracic ultrasound-guided percutaneous intramyocardial injection combined with ultrasound-targeted microbubble destruction-mediated angiogenin 1 gene therapy in canine myocardial infarction model.Cardiovascular diagnosis and therapy · 2021Article
- Overexpression of Kdr in adult endocardium induces endocardial neovascularization and improves heart function after myocardial infarction.Cell research · 2021Article
- M1 Bone Marrow-Derived Macrophage-Derived Extracellular Vesicles Inhibit Angiogenesis and Myocardial Regeneration Following Myocardial Infarction via the MALAT1/MicroRNA-25-3p/CDC42 Axis.Oxidative medicine and cellular longevity · 2021Article
- Genetic lineage tracing reveals poor angiogenic potential of cardiac endothelial cells.Cardiovascular research · 2021Article
- Coronary vessel formation in development and disease: mechanisms and insights for therapy.Nature reviews. Cardiology · 2020Review
- Experimental artefacts can lead to misattribution of bioactivity from soluble mesenchymal stem cell paracrine factors to extracellular vesicles.Journal of extracellular vesicles · 2020Article
- Biomaterials Loaded with Growth Factors/Cytokines and Stem Cells for Cardiac Tissue Regeneration.International journal of molecular sciences · 2020Review
- Therapeutic Potential of Hydroxysafflor Yellow A on Cardio-Cerebrovascular Diseases.Frontiers in pharmacology · 2020Review
- Tumor Angiogenesis and Anti-Angiogenic Strategies for Cancer Treatment.Journal of clinical medicine · 2019Review
- Liraglutide Increases VEGF ExpressionFrontiers in pharmacology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the recent past, substantial advances have been made in the treatment of myocardial infarction (MI). Despite the impact of these positive developments, MI remains to be a leading cause of morbidity as well as mortality. An interesting hypothesis is that the development of new blood vessels (angiogenesis) or the remodeling of preexisting collaterals may form natural bypasses that could compensate for the occlusion of an epicardial coronary artery. A number of angiogenic factors are proven to be elicited during MI. Exogenous supplementation of these growth factors either in the form of recombinant protein or gene would enhance the collateral vessel formation and thereby improve the outcome after MI. The aim of this review is to describe the nature and potentials of different angiogenic factors, their expression, their efficacy in animal studies, and clinical trials pertaining to MI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.